Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-29T17:28:41.974Z Has data issue: false hasContentIssue false
  • English
  • Français

Symptom improvement is associated with serum cytokine level change during RTMS tretament in patients with treatment resistant depression

Published online by Cambridge University Press:  13 August 2021

J. Lazary ,
M. Elemery ,
S. Kiss ,
L. Pogany  and
G. Faludi
J. Lazary*
Affiliation:
Department Of General Psychitary B, Nyírő Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary
M. Elemery
Affiliation:
Janos Szentagothai Neuroscience Doctoral School, Semmelweis University, Budapest, Hungary
S. Kiss
Affiliation:
Janos Szentagothai Neuroscience Doctoral School, Semmelweis University, Budapest, Hungary
L. Pogany
Affiliation:
Department Of General Psychitary B, Nyírő Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary
G. Faludi
Affiliation:
Department Of General Psychitary B, Nyírő Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Introduciton: Repetetive transcranial magnetic stimulation (rTMS) is an effective and safety noninvasive technique for treatment of major depression disorder (MDD). There is a body of increasing evidences on the potential molecular mechanisms underlying its effectivity even in case of treatment resistant depression (TRD), however, the exact mechanism is still not clarified. Among multiple biological systems, inflammation can be a target of rTMS in MDD (Tian et al. 2020; Tateishi et al. 2020).

Objectives

Here we analysed serum cytokine levels in TRD before and after rTMS interventions.

Methods

We used bilateral stimulation (15Hz for left DLPC and 1Hz on the right side) in 18 patients with TRD (5 men and 13 women; mean age=47.7±12.1 year) for 2x5 days. Blood samples were collected before the first (V1) and after the last inetrevntion (V2). Phenotypic changes were measured by Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Snaith–Hamilton Pleasure Scale (SHAPS), Insomnia Severity Index (ISI) and Stroop Color-Word Test (SCWT) modified by Golden. Inflammatory cytokines were assessed by ELISA assays.

Results

Change of BDI and BAI scores between V1 and V2 is associated with difference of TNFalpha levels (p=0.043; adj.R2=0.42 p=0.011; adj R2=0.43). Decrease on SHAPS score has been depended on IL-6 level (p=0.027) and the interaction of TNFalpha and IL-10 (p=0.005; adj R2=0.63). Sleep disturbance and neurocognitive function was not associated with cytokine levels.

Conclusions

Our results confirmed the association between depressive, anxious and anhedonia symptom improvement and inflammatory mechansims during rTMS treatment. The study was supported by the OTKA 151513 grant.

Keywords

rTMSTRDDepressionnoninvasive brain stimulation
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S492
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.